trilaciclib   Click here for help

GtoPdb Ligand ID: 9626

Synonyms: Cosela® | G1T28
Approved drug Immunopharmacology Ligand
trilaciclib is an approved drug (FDA (2021))
Compound class: Synthetic organic
Comment: Trilaciclib (G1T28) is a short-acting CDK4/6 inhibitor that was developed by G1 Therapeutics [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 91.21
Molecular weight 446.25
XLogP 3.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CCN(CC1)c1ccc(nc1)Nc1ncc2c(n1)n1c(c2)C(=O)NCC21CCCCC2
Isomeric SMILES CN1CCN(CC1)c1ccc(nc1)Nc1ncc2c(n1)n1c(c2)C(=O)NCC21CCCCC2
InChI InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
InChI Key PDGKHKMBHVFCMG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Pre-chemotherapy intravenous administration of G1T28 was evaluated in a number of clinical trials, in patients with advanced solid tumours- small cell lung cancer (NCT03041311) and triple-negative breast cancer (NCT02978716). It was approved by the FDA in February 2021, as a myelopreservation therapy indicated for patients receiving chemotherapy for small cell lung cancer.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
G1T28 represents a novel strategy for targeting CDK4/6-independent tumours. By transiently inhibiting CDK4/6 in normal hematopoietic stem cells, and thereby protecting them from chemotherapy-induced exhaustion, it is predicted that this strategy will deliver better outcomes for cancer patients receiving chemotherapy (i.e. reduced chemotherapy-induced myelosuppression) [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02978716 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Phase 2 Interventional G1 Therapeutics, Inc.
NCT03041311 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) Phase 2 Interventional G1 Therapeutics, Inc.